Effects of the NMDA receptor antagonist D-CPPene on extracellular levels of dopamine and dopamine and serotonin metabolites in striatum of kindled and non-kindled rats

European Journal of Pharmacology

Volumn 374, Issue 2, 1999, Pages 175-187

  Potschka, Heidrun ^a   Fedrowitz, Maren ^a   Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Caudate putamen; Epilepsy; Glutamate

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMPHETAMINE; DOPAMINE; HOMOVANILLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOMIFENSINE; PARGYLINE;

ANIMAL EXPERIMENT; ATAXIA; BEHAVIOR DISORDER; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STEREOTYPY;

EID: 0032991081     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00311-8     Document Type: Article

References (77)

1. Adamec R.E. Does kindling model anything clinically relevant? Biol. Psychiatry. 27:1990;249-279.
2. Alkhatib I., Karadag H.C., Ulugol A. The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats. Pharmacol. Biochem. Behav. 52:1995;723-730.
3. Becquet D., Faudon M., Hery F. In vivo evidence for an inhibitory glutamatergic control of serotonin release in the cat caudate nucleus: involvement of GABA neurons. Brain Res. 519:1990;82-88.
4. Behrens S., Gattaz W.F. MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. J. Neural Transm. 90:1992;219-224.
5. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur. J. Pharmacol. 200:1991;1-8.
6. Bowers M.B., Morton J.B. Regional brain catecholamines and metabolites following THC, PCP and MK-801. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;961-964.
7. Bubser M., Keseberg U., Notz P.K., Schmidt W.J. Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229:1992;75-82.
8. Carboni E., Imperato A., Perezzani L., Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience. 28:1989;653-661.
9. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
10. Carter A.J. Microbore high-performance liquid chromatographic method for the measurement of dopamine and its metabolites: recommendations for optimal sample collection and storage. J. Chromatogr. 660:1994;158-163.
11. Chapman C.D., Gazzara R.A., Howard S.G. Effects of phencyclidine on extracellular levels of dopamine, dihydroxyphenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology. 29:1990;319-325.
12. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist induced behaviors. Psychopharmacology. 120:1995;67-74.
13. Csernansky J.G., Kerr S., Pruthi R., Prosser E.S. Mesolimbic dopamine receptor increases two weeks following hippocampal kindling. Brain Res. 449:1988;357-360.
14. Csernansky J.G., Mellentin J., Beauclair L., Lombronzo L. Mesolimbic dopaminergic supersensitivity following electrical kindling of the amygdala. Biol. Psychiatry. 23:1988;285-294.
15. Dai H.L., Gebhardt K., Carey R.J. Time course effects of MK-801: the relationship between brain neurochemistry and behavior. Brain Res. Bull. 36:1995;175-180.
16. Dazzi L., Serra M., Porceddu M.L., Sanna A., Chessa M.F., Biggio G. Enhancement of basal and pentylenetetrazol (PTZ)-stimulated dopamine release in the brain of freely moving rats by PTZ-induced kindling. Synapse. 26:1997;351-358.
17. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 17:1994;228-233.
18. Dürmüller N., Craggs M., Meldrum B.S. The effect of the non-NMDA receptor antagonists GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 17:1994;167-174.
19. French E.D., Mura A., Ting W. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10-dopamine neurons. Comparison to competitive NMDA antagonists. Synapse. 13:1993;108-116.
20. 2 receptor mRNA expression in basal ganglia following kindling. Epilepsy Res. 17:1994;23-29.
21. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B., Meissner I., Murphy D., Larue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke. 26:1995;602-605.
22. Gruen R.J., Roth R.H., Bunney B.S., Moghaddam B. Increase in striatal dopamine release following local perfusion of the NMDA receptor antagonist 2-amino-5-phosphonopentanoic acid. Soc. Neurosci. Abstr. 16:1990;679.
23. Hadjiconstantinou M., Rossetti Z.L., Wemlinger T.A., Neff N.H. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity. Eur. J. Pharmacol., Mol. Pharmacol. 289:1995;97-101.
24. Herrling, P.L., Emre, M., Watkins, J.C., 1997. D-CPPene (SDZ EAA-494) - a competitive NMDA antagonist: pharmacology and results in humans. In: Herrling, P.L. (Ed.), Excitatory Amino Acids - Clinical Results with Antagonists. Academic Press, San Diego, pp. 7-21.
25. Hiramatsu M., Cho A.K., Nabeshima T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. 166:1989;359-366.
26. Hubner C.B., Pert A. Phencyclidine, but not MK-801, produces increases in extracellular dopamine levels as assessed by in vivo microdialysis. Soc. Neurosci. Abstr. 16:1990;583.
27. Imperato A., Scrocco M.G., Bacchi S., Angelucci L. NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol. 187:1990;555-556.
28. 2 receptor regulation unilaterally. Soc. Neurosci. Abstr. 17:1991;611.
29. Keefe K.A., Zigmond M.J., Abercrombie E.D. In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids. J. Neural Transm.: Gen. Sect. 91:1993;223-240.
30. Kiss J.P., Toth E., Lajtha A., Vizi E.S. NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat - a microdialysis study. Brain Res. 641:1994;145-148.
31. Krebs M.O., Trovero F., Desban M., Gauchy C., Glowinski J., Kemel M.L. Distinct presynaptic regulation of dopamine release through NMDA receptors in striosome- and matrix-enriched areas of the rat striatum. J. Neurosci. 11:1991;1256-1262.
32. 2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice. Behav. Brain Res. 70:1995;145-151.
33. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 54:1998;721-741.
34. Löscher W., Hönack D. Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol. Sci. 12:1991;52.
35. 1A receptors. J. Pharmacol. Exp. Ther. 257:1991;1146-1153.
36. Löscher W., Hönack D. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215:1992;199-208.
37. 1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 242:1993;99-104.
38. Löscher W., Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17:1994;95-134.
39. Löscher W., Annies R., Hönack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191-194.
40. Löscher W., Annies R., Hönack D. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur. J. Pharmacol. 242:1993;263-274.
41. Löscher W., Wlaz P., Szabo L. Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats. Neurosci. Lett. 240:1998;33-36.
42. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
43. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine- stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 40:1996;57-62.
44. 3H ]acetylcholine release from rat prefrontal cortex and striatal slices Brain Res. 592:1992;115-121.
45. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
46. Moghaddam B., Bolinao M.L. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse. 18:1994;337-342.
47. Murase S., Mathe J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity. Differential actions on firing pattern related to anatomical localization. J. Neural Transm. 91:1993;13-25.
48. Nabeshima T., Yamaguchi K., Hiramatsu M., Amano M., Furukawa H., Kameyama T. Serotonergic involvement in phencyclidine-induced behaviors. Pharmacol. Biochem. Behav. 21:1984;401-412.
49. Ohmori T., Nakamura F., Koyama T., Yamashita I. Amygdala kindling does not alter the N-methyl-D-aspartate receptor-channel complex which modulates dopamine release in the rat striatum and amygdala. Brain Res. 587:1992;257-262.
50. 2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology. 111:1993;427-434.
51. Pani L., Gessa G.L., Carboni S., Portas C.M., Rossetti Z.L. Brain dialysis and dopamine - does the extracellular concentration of dopamine reflect synaptic release? Eur. J. Pharmacol. 180:1990;85-90.
52. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, Sydney.
53. Ping H.X., Xie L., Gong X.J., Liu G.Q., Wu H.Q. Effect of dizocilpine maleate on monoamines and their metabolites in rat brain. Acta Pharmacol. Sin. 13:1992;206-208.
54. Rao T.S., Kim H.S., Lehmann J., Martin L.L., Wood P.L. Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site. Tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors. Neuropharmacology. 29:1990;225-231.
55. Rao T.S., Kim H.S., Lehmann J., Martin L.L., Wood P.L. Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system. Regional studies in the rat. J. Neurochem. 54:1990;1157-1162.
56. Rao T.S., Cler J.A., Mick S.J., Emmett M.R., Farah J.M., Contreras P.C., Iyengar S., Wood P.L. Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system. Functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathway. J. Neurochem. 56:1991;907-913.
57. 3H ]dopamine turnover in striatum and frontal cortex in vivo linked to glutamate receptor antagonism J. Neurochem. 70:1998;1979-1985.
58. Santiago M., Westerink B.H.C. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J. Neurochem. 57:1991;738-747.
59. Schmidt W.J. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotype that is antagonized by haloperidol and clozapine. Psychopharmacology. 90:1986;123-126.
60. Schmidt W.J., Bury D. Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the rat. Life Sci. 43:1988;545-551.
61. Spanagel R., Eilbacher B., Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmacokinetic microdialysis study. Eur. J. Pharmacol. 262:1994;21-26.
62. Steinpreis R.E., Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine. A microdialysis and behavioral study. Brain Res. 612:1993;263-270.
63. Strecker R.E., Moneta M.E. Electrical stimulation of the kindled hippocampus briefly increases extracellular dopamine in the nucleus accumbens. Neurosci. Lett. 176:1994;173-177.
64. Sveinbjornsdottir S., Sander J.W.A.S., Upton D., Thompson P.J., Patsalos P.N., Hirt D., Emre M., Lowe D., Duncan J.S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16:1993;165-174.
65. Wang J.K. Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes. J. Neurochem. 57:1991;819-822.
66. Waters N., Lundgren C., Hansson L.O., Carlsson M.L. Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. J. Neural Transm. 103:1996;117-129.
67. Wedzony K., Czyrak A., Mackowiak M., Fijal K. The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;517-527.
68. Westerink B.H., Kikkert R.J. Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J. Neurochem. 46:1986;1145-1152.
69. Westerink B.H., Korf J. Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brain. Eur. J. Pharmacol. 37:1976;249-255.
70. Whitton P.S., Biggs C.S., Pearce B.R., Fowler L.J. Regional effects of MK-801 on dopamine and its metabolites studied by in vivo microdialysis. Neurosci. Lett. 142:1992;5-8.
71. Whitton P.S., Biggs C.S., Pearce B.R., Fowler L.J. MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J. Neurochem. 58:1992;1573-1575.
72. Whitton P.S., Maione S., Biggs C.S., Fowler L.J. N-methyl-D-aspartate receptors modulate extracellular dopamine concentration and metabolism in rat hippocampus and striatum in vivo. Brain Res. 635:1994;312-316.
73. Whitton P.S., Richards D.A., Biggs C.S., Fowler L.J. N-methyl-D-aspartate receptors modulate extracellular 5-hydroxytryptamine concentration in rat hippocampus and striatum in vivo. Neurosci. Lett. 169:1994;215-218.
74. Willetts J., Balster R.L., Leander J.D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11:1990;423-428.
75. Wlaz P., Ebert U., Potschka H., Löscher W. Electrical but not chemical kindling increases sensitivity to some phencyclidine-like behavioral effects induced by the competitive NMDA receptor antagonist D-CPPene in rats. Eur. J. Pharmacol. 353:1998;177-189.
76. Wood P.L., Kim H.S., Marien M.R. Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release. Life Sci. 41:1987;1-5.
77. Zetterström T., Sharp T., Collin A.K., Ungerstedt U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs: implications for the origin of extracellular DOPAC. Eur. J. Pharmacol. 148:1988;327-334.